p-Aminosalicylic acid(PAS)Granules (4 gmpackets) can bemixed with food;tablets (500 mg) arestill available in somecountries, but not inthe United States; asolution forintravenousadministration isavailable in EuropeLevofloxacin Tablets (250 mg, 500mg, 750 mg);aqueous solution(500 mg vials) forintravenousinjectionsMoxifloxacinTablets (400 mg);aqueous solution(400 mg/250 mL) forintravenous injectionAdultsChildrenAdultsChildrenAdults8-12 gm/day in two orthree doses200-300 mg/kg/d in two tofour divided doses (10gm)500-1,000 mg daily^^400 mg dailyThere are no data tosupport intermittentadministrationThere are no data tosupport intermittentadministrationThere are no data tosupport intermittentadministration^^There are no data tosupport intermittentadministrationThere are no data tosupport intermittentadministrationThere are no data tosupport intermittentadministrationThere are no data tosupport intermittentadministration^^There are no data tosupport intermittentadministrationThere are no data tosupport intermittentadministrationThere are no data tosupport intermittentadministrationThere are no data tosupport intermittentadministration^^There are no data tosupport intermittentadministrationChildren‡‡‡‡‡‡*Dose per weight is based on ideal body weight. Children weighing more than 40 kg should be dosed as adults.† For purposes of this document adult dosing begins at age 15 years.‡ Dose may need to be adjusted when there is concomitant use of protease inhibitors or nonnucleoside reverse transcriptase inhibitors.§ The drug can likely be used safely in older children but should be used with caution in children less than 5 years of age, in whom visual acuity cannot be monitored. In youngerchildren, ethambutol at the dose of 15 mg/kg per day can be used if there is suspected or proven resistance to isoniazid or rifampin. It should be noted that, although this is the dose recommended generally, most clinicians with experience using cycloserine indicate that it is unusual for patients to be able totolerate this amount. Serum concentration measurements are often useful in determining the optimal dose for a given patient.# The single daily dose can be given at bedtime or with the main meal.** Dose: 15 mg/kg per day (1 gm) and 10 mg/kg in persons more than 59 years of age (750 mg). Usual dose: 750-1000 mg administered intramuscularly or intravenously, given as asingle dose 5-7 days/week and reduced to two or three times per week after the first 2-4 months or after culture con<strong>version</strong>, depending on the efficacy of the other drugs in theregimen.^^ The long-term (more than several weeks) use of levofloxacin in children and adolescents has not been approved because of concerns about effects on bone and cartilage growth.However, most experts agree that the drug should be considered for children with tuberculosis caused by organisms resistant to both isoniazid and rifampin. The optimal dose is notknown.‡‡ The long-term (more than several weeks) use of moxifloxacin in children and adolescents has not been approved because of concerns about effects on bone and cartilage growth.The optimal dose is not known.
Table 2 Suggested pyrazinamide doses, using whole tablets, for adults weighing 40-90 kilogramsWeight (kg)*40-55 56-75 76-90Daily, mg (mg/kg) 1,000 (18.2 – 25) 1,500 (20 – 26.8) 2,000 † (22.2 – 26.3)Three times weekly, mg (mg/kg) 1,500 (27.3 – 37.5) 2,500 (33.3 – 44.6) 3,000 † (33.3 – 39.5)Twice weekly, mg (mg/kg) 2,000 (36.4 – 50) 3,000 (40 – 53.6) 4,000 † (44.4 – 52.6)*Based on estimated lean body weight.Maximum dose regardless of weight.Table 3 Suggested ethambutol doses, using whole tablets, for adults weighing 40-90 kilogramsWeight (kg)*40-55 56-75 76-90Daily, mg (mg/kg) 800 (14.5 – 20) 1,200 (16 – <strong>21</strong>.4) 1,600 † (17.8 – <strong>21</strong>.1)Three times weekly, mg (mg/kg) 1,200 (<strong>21</strong>.8 – 30) 2,000 (26.7 – 35.7) 2,400 † (26.7 – 31.6)Twice weekly, mg (mg/kg) 2,000 (36.4 – 50) 2,800 (37.3 – 50) 4,000 † (44.4 – 52.6)*Based on estimated lean body weight.Maximum dose regardless of weight.
- Page 2 and 3:
PREFACEThe Antimicrobial Use Guidel
- Page 4 and 5:
Antimicrobial Cost Table (Cost info
- Page 6 and 7:
Summary of Antibiotic Order Form: S
- Page 8:
LUNGS/PULMONARYCommunity-Acquired P
- Page 12 and 13:
PART I: BY DRUGABACAVIRFor up-to-da
- Page 14 and 15:
constructed systemic-pulmonary shun
- Page 16 and 17:
AMPICILLIN/SULBACTAM (Unasyn ® )Us
- Page 18 and 19:
ATOVAQUONE/PROGUANIL (Malarone ® )
- Page 20 and 21:
CEFAZOLINUsual DoseAdult: Moderate/
- Page 22 and 23:
CommentsDose adjustment required fo
- Page 24 and 25:
1. Typhoid fever. (NOTE: Third-gene
- Page 26 and 27:
-Dutasteride-Eltrombopag-Theophylli
- Page 28 and 29:
CLINDAMYCINUsual DoseAdult: 600-900
- Page 30 and 31:
DAPTOMYCINInfectious Disease approv
- Page 32 and 33: Concurrent administration with peni
- Page 34 and 35: • Cisapride (contraindicated) •
- Page 36 and 37: • Oral contraceptives/hormones -
- Page 38 and 39: Synergy in infective endocarditis a
- Page 40 and 41: • Colchicine • Indinavir • Ta
- Page 42 and 43: • Donepezil • Pioglitazone• D
- Page 44 and 45: with linezolid should be considered
- Page 46 and 47: 4. Life-threatening Gram-negative i
- Page 48 and 49: MOXIFLOXACINLevofloxacin and moxifl
- Page 50 and 51: Indications1. Uncomplicated cystiti
- Page 52 and 53: CommentsDose adjustment required fo
- Page 54 and 55: PIPERACILLIN/TAZOBACTAM (Zosyn ® )
- Page 56 and 57: PRIMAQUINEUsual DoseAdult: Malaria
- Page 58 and 59: RIFABUTINUsual DoseAdult (150 mg ca
- Page 60 and 61: • Chloramphenicol • Leflunomide
- Page 62 and 63: SULFISOXAZOLENo longer available as
- Page 64 and 65: TICARCILLIN/CLAVULANATE (Timentin
- Page 66 and 67: 2. Recurrent urinary tract infectio
- Page 68 and 69: VANCOMYCINUsual DoseAdult: 1 g Q12H
- Page 70 and 71: Careful monitoring of patients usin
- Page 72 and 73: APPENDIX B: UWHC SURGICAL ANTIMICRO
- Page 74 and 75: GI:Appendectomy 3Anaerobic organism
- Page 76 and 77: VascularLIKELYPATHOGENS• ANTIMICR
- Page 78 and 79: Cleanorthopedicprocedures(other)Sta
- Page 80 and 81: APPENDIX C: THERAPY FOR TUBERCULOSI
- Page 84 and 85: Appendix D: UNIVERSITY OF WISCONSIN
- Page 86 and 87: Appendix E: UWHC Guidelines for the
- Page 88 and 89: B. Antifungal Prophylaxis for BMT a
- Page 90 and 91: D. Cost ComparisonDrugAmphotericin
- Page 92 and 93: 17. Maertens J, Glasmacher A, Herbr
- Page 94 and 95: 47. Courtney R, Wexler D, Radwanski
- Page 96 and 97: 2.1.7 Patient is without placement
- Page 98 and 99: Medications Approved for Parenteral
- Page 100 and 101: APPENDIX G: Serum Drug Concentratio
- Page 102 and 103: APPENDIX H: Guidelines for Monitori
- Page 104 and 105: 1. Patients with large volumes of d
- Page 106 and 107: 16. Tsuji B, Rybak MJ. The influenc
- Page 108 and 109: APPENDIX I: Infectious Diseases App
- Page 110 and 111: APPENDIX J: UWHC Guidelines For the
- Page 112 and 113: with aztreonam and other beta-lacta
- Page 114 and 115: D. Side Chains1.2.5. The prescriber
- Page 116 and 117: 14. Pichichiro ME. Use of selected
- Page 118 and 119: Appendix KUWHC Guidelines for Cost-
- Page 120 and 121: sulfa and can be prescribed topatie
- Page 122 and 123: superinfection: amoxicillin 1 g PO
- Page 124 and 125: 17. Smucny J, Fahey T, Becker L, Gl
- Page 126 and 127: Appendix M: Guidelines for the Prop
- Page 128 and 129: D. CategorizationPatients should be
- Page 130 and 131: Empiric coverage for Enterococcus i
- Page 132 and 133:
H. Necrotizing PancreatitisThe publ
- Page 134 and 135:
Bone or JointEndocarditis 4Streptoc
- Page 136 and 137:
Candidemia or candidiasis 11Non-neu
- Page 138 and 139:
11. Pappas PG, Kauffman CA, Andes D
- Page 140 and 141:
piperacillin/tazobactam. There were
- Page 142 and 143:
D. Dose of Antibiotic1. Piperacilli
- Page 144 and 145:
TNAVasopressinVoriconazoleMeropenem
- Page 146 and 147:
pretreatment with an H1-histamine b
- Page 148 and 149:
formal consult is not required, but
- Page 150:
K. References1.0 Bliziotis IA, Ples